Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

Real-world data may serve as a benchmark for future studies in elderly patients with acute myeloid leukemia.

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Findings suggest investigating an individualized monitoring period for stable patients with hematologic cancers to decrease financial and geographic barriers to CAR T-cell therapy.

In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.